ClinicalTrials.gov record NCT01408225
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
This is an observational registry that collects clinical information and stores blood and bone marrow samples from people with plasma cell disorders, including MGUS, AL amyloidosis, and multiple myeloma. It tracks treatments, outcomes, patient-reported health, complications, remission length, and survival. The study team provides two-way contact and information to participants and may inform them about related clinical trials. The resource is intended to support future research.
What it is studying. The study is building a data and tissue/blood sample resource to monitor disease course and treatments over time and to support research into plasma cell disorders and related clinical studies.
What the researchers hope to learn. Create a shared database and sample bank to enable research into disease course, patient-reported outcomes, morbidity, survival, and to support development of better treatments for plasma cell disorders.
What this study is about
The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.
The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals:
- Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, how they feel, what complications they suffer, how long they stay in remission, and how long they live.
- Contact: Because myeloma and amyloidosis are rare, less than 700 patients are diagnosed in the state of Ohio each year, patients often feel they don't have accurate information. The investigators want to provide them access to our clinical team (both phone and email consultations, even office visits for patients that can come to Columbus) as well as information regarding informational events pertaining to your disease and local support groups.
- Research: Because nearly all myeloma and amyloid patients relapse and treatment is eventually unsuccessful, our focus is to develop more effective treatments that not only prolong life, but cure the disease. Periodically the investigators will inform them about clinical trials studying new drugs or treatment paradigms.
Interventions being studied
Being studied in this trial does not mean the treatment or procedure is approved or available for this condition.
- Procedure
- tissue banking
Eligibility
The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.
Inclusion criteria
- Inclusion:
- Diagnosis of a plasma cell dyscrasia
- Exclusion:
- Prisoners are excluded from participation as they have no standard access to the Ohio State myeloma clinic and would impede the research objective of this protocol.
Study description and what participation involves
The study's detailed description, as published on ClinicalTrials.gov.
Detailed description from the registry
The investigators propose to contact and interact with all patients with plasma cell dyscrasias in the State of Ohio (and all patients diagnosed or treated at Ohio State Medical Center) for both surveillance and research purposes in order to develop interventions targeted to decrease their morbidity and mortality.
AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
Participants provide medical information for a database and may give blood samples and bone marrow tissue for storage (tissue banking) at diagnosis, during routine follow-up, or at relapse. They can expect periodic contact by phone or email, possible in‑person clinic visits, and questionnaires about symptoms and quality of life. The study team may inform participants about, and sometimes offer enrollment in, other observational or therapeutic studies. Follow-up and data/samples may be collected over time (the registry's planned duration is up to 10 years).
How the study is structured. An observational, prospective cohort registry. Participants give clinical information and may provide blood and bone marrow samples at diagnosis, routine follow-up, or relapse; they are followed over time (target duration listed as 10 years). No treatments are assigned by the study.
Questions you could ask
These questions are suggestions for a conversation with the study team or your own clinician, not advice.
- This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
- The listed sites are in United States. Is any of them reachable for me, and does the study help with travel?
- Which of the eligibility criteria would need to be checked with tests before I could join?
More on AL amyloidosis
Important dates
- Study start
- Mar 17, 2011
- Primary completion
- March 2050 (estimated)
- Study completion
- March 2050 (estimated)
- Target enrollment
- 5000 participants (estimated)
- Last updated on registry
- Mar 23, 2026
- Data verified
- Oct 10, 2026
Sponsor and research team
The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Principal investigator
- Don Benson, Principal Investigator
Ohio State University Comprehensive Cancer Center
Central study contact
If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.
- The Ohio State University Comprehensive Cancer Center 📞 1-800-293-5066 ✉ OSUCCCClinicaltrials@osumc.edu
Participating sites (1)
- Ohio State University Medical CenterRecruiting
Columbus, Ohio, 43210 · United States
- Don Benson · 614-293-3818 · MyelomaRegistry@osumc.edu
- · 614-293-8858 · Don.Benson@osumc.edu
- Don Benson, MD
Terms used on this page · explanations by MedicalUpdates.ai
- relapse
- A condition that improved with treatment and has since returned or worsened.
The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.
← Back to clinical trials